

**REMARKS**


This Amendment is made in response to the Official Action mailed January 7, 2004. The Examiner, due to a consideration of the application by the Primary Examiner, has revisited prosecution. New claims 15-17 have been added and are directed to the elected embodiments of the invention. Accordingly, claims 9-13 and 15-17 are now pending in this application.

Applicants are now required to elect a single disease species as well as a single NK-3 antagonist compound to which the claims shall be restricted if no generic claim is finally held to be allowable. Applicants hereby elect benign prostatic hyperplasia as the disease species. New claim 15 is directed to the elected disease species of benign prostatic hyperplasia. Applicants also hereby elect ((S)-(-)-N-( $\alpha$ -Ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide) as the single NK-3 receptor antagonist compound species. New claims 16 and 17 are directed to this elected compound species.

Support for the addition of new claims 15-17 can be found in the claims and specification as originally filed. No new matter has been added.

In view of the foregoing, favorable reconsideration of claims 9-13, favorable consideration of new claims 15-17 and allowance of this application with claims 9-13 and 15-17 are earnestly solicited.

Respectfully submitted,

  
Nora Stein-Fernandez  
Attorney for Applicants  
Registration No. 36,689

GLAXOSMITHKLINE  
Corporate Intellectual Property-UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone: (610) 270-5044  
Facsimile: (610) 270-5090  
n:\nsf\patapps\P50869\Restriction Requirement Election.doc